Form 4: Silexion Therapeutics Officer Reports Share Transactions

Silexion Therapeutics Corp. officer Mitchell Shirvan reports acquisition of 6,000 ordinary shares via settled RSUs and provides updated derivative security ownership following a 1-for-10 reverse stock split.

Summary

• Mitchell Shirvan, CSO and CDO of Silexion Therapeutics Corp., reported a transaction on June 4, 2026.
• This transaction involved the grant and immediate settlement of 6,000 fully vested Restricted Stock Units (RSUs) for ordinary shares, in recognition of services rendered.
• The filing also details an adjustment to previously held stock options due to a 1-for-10 reverse stock split that occurred on May 28, 2026.
• Following the reverse split, the number of options held by Shirvan was adjusted from 478 to 48, with the exercise price per share adjusted from $907.71 to $9,077.10.
• Similarly, the number of ordinary shares beneficially owned was adjusted from 27,889 to 2,789 prior to the RSU grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting routine insider transactions and corporate actions. While the RSU grant is positive for the executive, the reverse stock split and increased option exercise price introduce potential complexities.

Positives

• Grant of 6,000 RSUs to an officer, indicating continued equity-based compensation and potential alignment of interests.
• The officer's beneficial ownership of ordinary shares increased by 6,000 shares.
• The filing clarifies ownership details after a significant corporate action (reverse stock split).

Negatives

• The exercise price of stock options has significantly increased due to the reverse stock split, potentially making them less attractive to exercise.
• The reverse stock split itself can sometimes be perceived negatively by the market, often indicating a company's effort to boost its share price.

Risks

• The high exercise price of the adjusted stock options ($9,077.10) may pose a challenge for future exercise and potential dilution.
• The reverse stock split could signal underlying issues with the company's stock performance or market perception.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the adjusted stock option details suggest a future potential for dilution if options are exercised at the new, higher price.

Management Comments

• The grant of RSUs was approved by the Issuer's board of directors.
• The filing includes a Power of Attorney appointing Mirit Horenshtein Hadar, CFO, to prepare and execute SEC filings on behalf of officers and directors.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reverse stock split is a corporate action often undertaken by companies to meet exchange listing requirements or improve the perception of their stock price, though it does not change the fundamental value of the company.

Corporate Governance

Related Party Transactions

• The grant of 6,000 RSUs to Mitchell Shirvan (CSO and CDO) by Silexion Therapeutics Corp. is a related party transaction, approved by the board of directors.

Stakeholder Impact

• Shareholders: The RSU grant represents a form of compensation. The reverse stock split does not immediately change the value of their holdings but may affect market perception and liquidity.
• Employees: The RSU grant to a senior executive may set a precedent or be part of a broader compensation strategy.
• Management: The filing details transactions by a key officer, providing transparency on their equity holdings and compensation.

Next Steps

• Continued monitoring of Silexion Therapeutics Corp.'s stock performance and future SEC filings.
• Potential future exercise of stock options, which would result in the issuance of new shares and could impact beneficial ownership.

Key Dates

Keywords

Form 4, Silexion Therapeutics, Mitchell Shirvan, Restricted Stock Units, RSUs, Stock Options, Reverse Stock Split, Beneficial Ownership, SEC Filing, Insider Trading